Get the Stockscreener App
4.45
3.05%
-0.14
After Hours:
4.38
-0.07
-1.57%
Achieve Life Sciences Inc stock is traded at $4.45, with a volume of 602.96K.
It is down -3.05% in the last 24 hours and up +44.48% over the past month.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
See More
Previous Close:
$4.59
Open:
$4.67
24h Volume:
602.96K
Relative Volume:
0.43
Market Cap:
$227.42M
Revenue:
-
Net Income/Loss:
$-32.94M
P/E Ratio:
-4.009
EPS:
-1.11
Net Cash Flow:
$-24.95M
1W Performance:
-12.92%
1M Performance:
+44.48%
6M Performance:
+89.36%
1Y Performance:
-3.89%
1-Day Range:
$4.385
$4.67
1-Week Range:
$4.27
$5.145
52-Week Range:
$1.84
$5.78
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.45 | 234.57M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
Achieve Life Sciences Inc Stock (ACHV) Latest News
Is Achieve Life Sciences Inc. stock entering bullish territory - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock a fit for income portfoliosNew Guidance & Verified Swing Trading Watchlist - newser.com
How to recover losses in Achieve Life Sciences Inc. stockJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
Why Achieve Life Sciences Inc. stock could rally in 2025Market Risk Analysis & Real-Time Volume Trigger Notifications - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock a defensive play amid uncertainty2025 Key Highlights & Weekly High Return Opportunities - newser.com
Y Intercept Hong Kong Ltd Takes $263,000 Position in Achieve Life Sciences, Inc. $ACHV - MarketBeat
Is Achieve Life Sciences Inc. (SP4P) stock included in top ETFsPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - newser.com
Is Achieve Life Sciences Inc. stock near bottom after declineTrade Exit Summary & Low Risk High Win Rate Picks - newser.com
Is Achieve Life Sciences Inc. (SP4P) stock nearing a technical breakoutTrade Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Will Achieve Life Sciences Inc. stock return to pre crisis levels2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Can Achieve Life Sciences Inc. (SP4P) stock retain market dominancePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Achieve Life Sciences Inc. stock momentum explained2025 Earnings Surprises & Weekly Return Optimization Alerts - newser.com
HC Wainwright Issues Pessimistic Estimate for ACHV Earnings - MarketBeat
Can Achieve Life Sciences Inc. (SP4P) stock sustain institutional flows2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com
What dividend safety score for Achieve Life Sciences Inc. stockWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com
Why Achieve Life Sciences Inc. (SP4P) stock could outperform next yearRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch - MSN
Cash per share of Achieve Life Sciences, Inc. – DUS:SP4P - TradingView
Can Achieve Life Sciences Inc. stock deliver strong Q4 earningsEarnings Recap Report & Daily Profit Focused Screening - newser.com
Real time pattern detection on Achieve Life Sciences Inc. stock2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
When is the best time to exit Achieve Life Sciences Inc.2025 Performance Recap & Weekly High Momentum Picks - newser.com
Can Achieve Life Sciences Inc. stock withstand economic slowdown2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
Lake Street Keeps Their Buy Rating on Achieve Life Sciences (ACHV) - The Globe and Mail
Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Achieve Life Sciences Reports Q3 2025 Results - MSN
Will Achieve Life Sciences Inc. stock continue dividend increasesJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Total equity of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2025 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences: Key Insights from Earnings Call - The Globe and Mail
Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential - TipRanks
Return on equity % of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
What insider trading reveals about Achieve Life Sciences Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Cash from investing activities of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
Non-operating income (total) of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
Equity in earnings of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
Discontinued operations of Achieve Life Sciences, Inc. – HAM:SP4P - TradingView
Achieve Life Sciences, Inc. Dividends – HAM:SP4P - TradingView
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Achieve Life Sciences Inc (ACHV) Q3 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Achieve Life Sciences Inc (ACHV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Achieve Life Sciences Inc (ACHV) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Can Achieve Life Sciences Inc. (SP4P) stock sustain breakout momentumMarket Sentiment Summary & Consistent Growth Equity Picks - newser.com
What momentum shifts mean for Achieve Life Sciences Inc.July 2025 Short Interest & Low Risk High Win Rate Picks - newser.com
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
0.05%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):